Ozanimod showed a rapid onset of action and efficacy as extended induction therapy in patients with ulcerative colitis nonresponsive to biologics.

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

FAECAL microbiota transplantation (FMT) shows promise in treating ulcerative colitis (UC), with specific gut microbial ...